To evaluate the antibody-capturing ability of AC-NKs, trastuzumab-emtansine (T-DM1) and sacituzumab (SZ) were used to treat HER2-positive cancer cells, such as SK-BR-3 and BT-474, and Trop-2 positive cancer cells, such as SK-BR-3 and MCF-7, respectively. Here, ERBB2 is linked to cancer.